Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1): First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

Jesper van Breeschoten; Michel W. J. M. Wouters; Doranne L. Hilarius; John B. Haanen; Christian U. Blank; Maureen J. B. Aarts; Franchette W. P. J. van den Berkmortel; Jan-Willem B. de Groot; Geke A. P. Hospers; Ellen Kapiteijn; Djura Piersma; Roos S. van Rijn; Karijn P. M. Suijkerbuijk; Willeke A. M. Blokx; Bert-Jan J. ten Tije; Astrid A. M. van der Veldt; Art Vreugdenhil; Marye J. Boers-Sonderen; Alfonsus J. M. van den Eertwegh

doi:10.1038/s41416-021-01312-1

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1): First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

Jesper van Breeschoten
, Michel W. J. M. Wouters
, Doranne L. Hilarius
, John B. Haanen
, Christian U. Blank
, Maureen J. B. Aarts
, Franchette W. P. J. van den Berkmortel
, Jan-Willem B. de Groot
, Geke A. P. Hospers
, Ellen Kapiteijn
, Djura Piersma
, Roos S. van Rijn
, Karijn P. M. Suijkerbuijk
, Willeke A. M. Blokx
, Bert-Jan J. ten Tije
, Astrid A. M. van der Veldt
, Art Vreugdenhil
, Marye J. Boers-Sonderen
, Alfonsus J. M. van den Eertwegh^*

^*Corresponding author for this work

Dutch Institute for Clinical Auditing
Netherlands Cancer Institute
Red Cross Hospital, Beverwijk
University of Limburg
Sittard-Geleen
Isala Heart Center
University of Groningen
Leiden University
Medisch Spectrum Twente (MST)
Medical Centre Leeuwarden
Utrecht University
Amphia ziekenhuis
Erasmus University Rotterdam
Maxima Medical Centre
Radboud University Nijmegen

Research output: Contribution to journal › Comment/Letter to the editor › Academic

13 Downloads (Pure)

Abstract

Since the publication of this paper, the authors have noticed an error in the Abstract where the value for the 2-year overall survival

Original language	English
Pages (from-to)	1746
Number of pages	1
Journal	British journal of cancer
Volume	124
Issue number	10
Early online date	2021
DOIs	https://doi.org/10.1038/s41416-021-01312-1
Publication status	Published - 11 May 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41416-021-01312-1

Correction-first-line-brafmek-inhibitors-versus-anti-pd-1-monotherapy-in-brafv600-mutant-advanced-melanoma-patients-a.pdfFinal published version, 203 KBLicence: Taverne

Fingerprint

Dive into the research topics of 'Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1): First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)'. Together they form a unique fingerprint.

Cite this

van Breeschoten, J., Wouters, M. W. J. M., Hilarius, D. L., Haanen, J. B., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J.-W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Blokx, W. A. M., ten Tije, B.-J. J., van der Veldt, A. A. M., Vreugdenhil, A., Boers-Sonderen, M. J., & van den Eertwegh, A. J. M. (2021). Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1): First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1). British journal of cancer, 124(10), 1746. https://doi.org/10.1038/s41416-021-01312-1

van Breeschoten, Jesper ; Wouters, Michel W. J. M. ; Hilarius, Doranne L. et al. / Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1) : First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1). In: British journal of cancer. 2021 ; Vol. 124, No. 10. pp. 1746.

@article{4f771b5a0792440787ff8ede8e62a9ed,

title = "Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1): First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)",

abstract = "Since the publication of this paper, the authors have noticed an error in the Abstract where the value for the 2-year overall survival",

author = "\{van Breeschoten\}, Jesper and Wouters, \{Michel W. J. M.\} and Hilarius, \{Doranne L.\} and Haanen, \{John B.\} and Blank, \{Christian U.\} and Aarts, \{Maureen J. B.\} and \{van den Berkmortel\}, \{Franchette W. P. J.\} and \{de Groot\}, \{Jan-Willem B.\} and Hospers, \{Geke A. P.\} and Ellen Kapiteijn and Djura Piersma and \{van Rijn\}, \{Roos S.\} and Suijkerbuijk, \{Karijn P. M.\} and Blokx, \{Willeke A. M.\} and \{ten Tije\}, \{Bert-Jan J.\} and \{van der Veldt\}, \{Astrid A. M.\} and Art Vreugdenhil and Boers-Sonderen, \{Marye J.\} and \{van den Eertwegh\}, \{Alfonsus J. M.\}",

year = "2021",

month = may,

day = "11",

doi = "10.1038/s41416-021-01312-1",

language = "English",

volume = "124",

pages = "1746",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "10",

}

van Breeschoten, J, Wouters, MWJM, Hilarius, DL, Haanen, JB, Blank, CU, Aarts, MJB, van den Berkmortel, FWPJ, de Groot, J-WB, Hospers, GAP, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, Blokx, WAM, ten Tije, B-JJ, van der Veldt, AAM, Vreugdenhil, A, Boers-Sonderen, MJ & van den Eertwegh, AJM 2021, 'Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1): First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)', British journal of cancer, vol. 124, no. 10, pp. 1746. https://doi.org/10.1038/s41416-021-01312-1

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1): First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1). / van Breeschoten, Jesper; Wouters, Michel W. J. M.; Hilarius, Doranne L. et al.
In: British journal of cancer, Vol. 124, No. 10, 11.05.2021, p. 1746.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1)

T2 - First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

AU - van Breeschoten, Jesper

AU - Wouters, Michel W. J. M.

AU - Hilarius, Doranne L.

AU - Haanen, John B.

AU - Blank, Christian U.

AU - Aarts, Maureen J. B.

AU - van den Berkmortel, Franchette W. P. J.

AU - de Groot, Jan-Willem B.

AU - Hospers, Geke A. P.

AU - Kapiteijn, Ellen

AU - Piersma, Djura

AU - van Rijn, Roos S.

AU - Suijkerbuijk, Karijn P. M.

AU - Blokx, Willeke A. M.

AU - ten Tije, Bert-Jan J.

AU - van der Veldt, Astrid A. M.

AU - Vreugdenhil, Art

AU - Boers-Sonderen, Marye J.

AU - van den Eertwegh, Alfonsus J. M.

PY - 2021/5/11

Y1 - 2021/5/11

N2 - Since the publication of this paper, the authors have noticed an error in the Abstract where the value for the 2-year overall survival

AB - Since the publication of this paper, the authors have noticed an error in the Abstract where the value for the 2-year overall survival

UR - https://www.scopus.com/pages/publications/85102555905

U2 - 10.1038/s41416-021-01312-1

DO - 10.1038/s41416-021-01312-1

M3 - Comment/Letter to the editor

C2 - 33723402

SN - 0007-0920

VL - 124

SP - 1746

JO - British journal of cancer

JF - British journal of cancer

IS - 10

ER -

van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB et al. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 10.1038/s41416-020-01229-1): First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1). British journal of cancer. 2021 May 11;124(10):1746. Epub 2021. doi: 10.1038/s41416-021-01312-1

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this